Abstract
The elimination pharmacokinetics of cefoperazone, a new cephalosporin, were studied in 15 preterm infants ranging in gestational age from 32 to 36 weeks and in postnatal age from 1 to 6 days. The infants received a single dose of either 50 or 250 mg of cefoperazone per kg by intravenous infusion. Blood samples were collected at specified times after completion of the drug infusion and then assayed for cefoperazone. Pharmacokinetic parameters were determined by noncompartmental analysis. Mean values for plasma half-life, elimination rate constant, apparent steady-state volume of distribution, and total body clearance were 5.53 h, 0.15 h-1, 124 ml/kg, and 36 ml/h per kg, respectively, for the group receiving a 50-mg/kg dose and 5.76 h, 0.14 h-1, 111 ml/kg, and 35 ml/h per kg, respectively, for the group receiving a 250-mg/kg dose. Positive correlations between gestational age and clearance and elimination rate were detected. A 50-mg/kg dose every 12 h ensured adequate serum levels for most of the common neonatal pathogens. Other than a transient rise in eosinophils in four subjects, no adverse effects were noted.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Balant L., Dayer P., Rudhardt M., Allaz A. F., Fabre J. Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther. 1980;3(Spec Issue):50–59. [PubMed] [Google Scholar]
- Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug;68(8):1071–1074. doi: 10.1002/jps.2600680845. [DOI] [PubMed] [Google Scholar]
- Bolton W. K., Scheld W. M., Spyker D. A., Sande M. A. Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency. Antimicrob Agents Chemother. 1981 May;19(5):821–825. doi: 10.1128/aac.19.5.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Craig W. A. Single-dose pharmacokinetics of cefoperazone following intravenous administration. Clin Ther. 1980;3(Spec Issue):46–49. [PubMed] [Google Scholar]
- Jones R. N., Fuchs P. C., Barry A. L., Gavan T. L., Gerlach E. H., Sommers H. M. Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates. Clin Ther. 1980;3(Spec Issue):14–23. [PubMed] [Google Scholar]
- Kayser F. H. Microbiological studies on cefoperazone. Clin Ther. 1980;3(Spec Issue):24–33. [PubMed] [Google Scholar]
- Kurtz T. O., Winston D. J., Hindler J. A., Young L. S., Hewitt W. L., Martin W. J. Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother. 1980 Oct;18(4):645–648. doi: 10.1128/aac.18.4.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee C. S., Brater D. C., Gambertoglio J. G., Benet L. Z. Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm. 1980 Aug;8(4):335–346. doi: 10.1007/BF01059382. [DOI] [PubMed] [Google Scholar]
- Mashimo K., Kunii O. Clinical trials with cefoperazone in the field of internal medicine in Japan. Clin Ther. 1980;3(Spec Issue):159–172. [PubMed] [Google Scholar]
- Shibata K. Clinical trials with cefoperazone in the field of surgery in Japan. Clin Ther. 1980;3(Spec Issue):173–189. [PubMed] [Google Scholar]
- Shimizu K. Cefoperazone: absorption, excretion, distribution, and metabolism. Clin Ther. 1980;3(Spec Issue):60–79. [PubMed] [Google Scholar]
- Srinivasan S., Francke E. L., Neu H. C. Comparative pharmacokinetics of cefoperazone and cefamandole. Antimicrob Agents Chemother. 1981 Feb;19(2):298–301. doi: 10.1128/aac.19.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Welch D. F., Matsen J. M. Bactericidal activity of cefoperazone in comparison with other beta-lactam antibiotics and gentamicin. Clin Ther. 1980;3(Spec Issue):127–129. [PubMed] [Google Scholar]